Sara Amini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sara Amini has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Afsaneh Amiri
Department of Cardiology, Ahvaz Jundishapour University of Medical Sciences, Imam Khomeini Hospital, Ahvaz, Iran
1 shared publicationAfsoon Fazlinezhad
1 shared publication- Ahmad Amin
Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
1 shared publication Ali Gholamzadeh
Department of Pharmaceutical Science, Faculty of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran; †Department of Cardiology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran; ‡Department of Pharmacodynamics and Toxicology, Faculty of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran; and §Cardiac Electrophysiology Research Center, Rajaie Cardiovascular Medical and Research Center, Tehran University of Medical Sciences, Tehran, Iran
1 shared publicationAmir F. Fazelifar
1 shared publicationAmir H. Mohammadpour
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Medknow in Research in Cardiovascular Medicine
- Vol. 11 (1) , 6-12
Inpatient cardiology consultation for COVID-19: What are cardiologists' diagnostic approaches?
Aim: Despite concerns about cardiovascular implications in coronavirus disease-2019 (COVID-19) patients, not all COVID-19 patients are visited by cardiologists and recommended to perform comprehensive cardiovascular assessments including measurement of biomarkers and echocardiography. We aimed to investigate the reasons for seeking cardiology care and to assess our cardiologists' diagnostic approaches to COVID-19 patients with potential cardiovascular involvement. Methods and Results: In this prospective, observational study, data of all consecutive COVID-19 patients admitted to six designated hospitals for COVID-19 in Iran in whom bedside cardiology consultation was requested were collected. A total of 148 patients including 105 (71%) males were included. The mean age was 57 ± 17 years. The most common reasons for cardiology consultation were dyspnea (56.7%), chest pain (12.8%), and suspected arrhythmias (10.8%). The most common comorbidities were hypertension (40.5%), diabetes mellitus (19.6%), and coronary heart disease (18.9%). A 12-lead electrocardiography (ECG) was obtained in all patients. Point-of-care ultrasonography or limited transthoracic echocardiography (TTE) was performed in 106 (71.6%) patients, and complete TTE was performed in 35 (23.4%) patients. Cardiac troponin was measured in 63 (42.6%) patients, and N-terminal pro B-type natriuretic peptide level was measured in 34 (23%) patients. Overall, 51 (34.5%) patients underwent invasive mechanical ventilation, inotropes were used in 29 (19.6%) patients, and 40 (27%) patients died. Conclusions: While preventing unnecessary investigations, the cardiologists should not overlook the lifesaving role of ubiquitous diagnostic modalities (such as ECG and TTE) in early detection and management of cardiac involvement in COVID-19.
- 1 January 2022
- Published by Medknow in Research in Cardiovascular Medicine
- Vol. 11 (1) , 6-12
Open AccessInpatient cardiology consultation for COVID-19: What are cardiologists' diagnostic approaches?
Aim: Despite concerns about cardiovascular implications in coronavirus disease-2019 (COVID-19) patients, not all COVID-19 patients are visited by cardiologists and recommended to perform comprehensive cardiovascular assessments including measurement of biomarkers and echocardiography. We aimed to investigate the reasons for seeking cardiology care and to assess our cardiologists' diagnostic approaches to COVID-19 patients with potential cardiovascular involvement. Methods and Results: In this prospective, observational study, data of all consecutive COVID-19 patients admitted to six designated hospitals for COVID-19 in Iran in whom bedside cardiology consultation was requested were collected. A total of 148 patients including 105 (71%) males were included. The mean age was 57 ± 17 years. The most common reasons for cardiology consultation were dyspnea (56.7%), chest pain (12.8%), and suspected arrhythmias (10.8%). The most common comorbidities were hypertension (40.5%), diabetes mellitus (19.6%), and coronary heart disease (18.9%). A 12-lead electrocardiography (ECG) was obtained in all patients. Point-of-care ultrasonography or limited transthoracic echocardiography (TTE) was performed in 106 (71.6%) patients, and complete TTE was performed in 35 (23.4%) patients. Cardiac troponin was measured in 63 (42.6%) patients, and N-terminal pro B-type natriuretic peptide level was measured in 34 (23%) patients. Overall, 51 (34.5%) patients underwent invasive mechanical ventilation, inotropes were used in 29 (19.6%) patients, and 40 (27%) patients died. Conclusions: While preventing unnecessary investigations, the cardiologists should not overlook the lifesaving role of ubiquitous diagnostic modalities (such as ECG and TTE) in early detection and management of cardiac involvement in COVID-19.
- Open Access
- 1 June 2015
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 65 (6) , 555-561
Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction
Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI. We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI. A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI. High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required.
- 1 June 2015
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 65 (6) , 555-561
Open AccessErythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction
Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI. We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI. A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI. High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required.
- Open Access
- 30 June 2013
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 28 (6) , 672-674
Round Cell Liposarcoma Metastatic to the Heart
Myxoid liposarcoma is a soft tissue tumor in adults with rare cardiac involvement. We report a 50-year-old female with high grade round cell liposarcoma of the left knee with metastases to the right heart chambers. The tumor was located in the right atrium with extension to right ventricle. The Patient underwent radiotherapy after surgical resection and 12-month follow-up revealed no recurrent cardiac disease.
- 30 June 2013
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 28 (6) , 672-674
Open AccessRound Cell Liposarcoma Metastatic to the Heart
Myxoid liposarcoma is a soft tissue tumor in adults with rare cardiac involvement. We report a 50-year-old female with high grade round cell liposarcoma of the left knee with metastases to the right heart chambers. The tumor was located in the right atrium with extension to right ventricle. The Patient underwent radiotherapy after surgical resection and 12-month follow-up revealed no recurrent cardiac disease.